Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2023 Earnings Call Transcript

1mon ago, source: InvestingChannel on MSN

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2023 Earnings Call Transcript March 19, 2024 Relmada Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.84, expectations were $-0.88.

Relmada Therapeutics Inc RLMD

3d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results

1mon ago, source: Yahoo Finance

CORAL GABLES, Fla., March 19, 2024 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today ...

Optimistic Buy Rating for Relmada Therapeutics Amidst Strong Phase 3 Trial Prospects and Financial Stability

1mon ago, source: Business Insider

Relmada Therapeutics (RLMD) Company Description: Relmada Therapeutics, Inc. is a clinical-stage biotechnology company. It engages in the development of d-methadone receptor antagonist, which is a ...

Relmada Therapeutics Inc

3mon ago, source: CNN

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in addressing diseases of the central nervous system. It develops esmethadone, an N-methyl-D-aspartate receptor ...

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2023 Earnings Call Transcript

1mon ago, source: Insider Monkey

Relmada Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.84, expectations were $-0.88. RLMD isn’t one of the 30 most popular stocks among hedge funds at the end of the third ...

Relmada Therapeutics, Inc.: Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results

1mon ago, source: Finanznachrichten

CORAL GABLES, Fla., March 19, 2024 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today ...

Relmada Therapeutics Inc RLMD

6d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2023 Earnings Call Transcript

1mon ago, source: Insider Monkey

And to close, I’m grateful to the Relmada team, for their continued hard work and dedication to executing on our mission. And I would also like to extend my sincere thanks, to the patients and ...

Relmada Therapeutics Inc.

1y ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Q4 2023 Relmada Therapeutics Inc Earnings Call

1mon ago, source: Yahoo Finance

Q4 2023 Relmada Therapeutics Inc Earnings Call Q4 2023 Relmada Therapeutics Inc Earnings Call HOME MAIL NEWS FINANCE SPORT CELEBRITY STYLE WEATHER MORE... Yahoo Finance Sign in Mail Sign in to view ...